Nurix Therapeutics, Inc.

Listed Company

NRIXCIK 0001549595NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Nov 30

Period

FY 2025

Revenue

$83.98M

Net Income

$-264.46M

Total Assets

$688.13M

Equity

$538.75M

Shares Out

103.41M

Op. Cash Flow

$-249.47M

NRIX$23.13+91.43% · past yearDBEQ Basic

Daily closing prices

Business

Nurix Therapeutics is a clinical-stage biopharmaceutical company discovering and developing targeted protein degradation medicines for cancer and inflammatory diseases. The company offers three clinical-stage drug candidates: bexobrutideg (a BTK degrader), zelebrudomide (a dual BTK and cereblon neosubstrate degrader), and NX-1607 (a CBL-B inhibitor), along with a preclinical pipeline including degrader antibody conjugates. Nurix operates through wholly owned programs and partnership collaborations with Gilead, Sanofi, and Pfizer, leveraging its proprietary DEL-AI platform to identify novel small-molecule degraders across oncology, inflammation, and immunology indications globally.

Summary from 10-K filed 2026-01-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-11-30	FY 2024 2024-11-30	FY 2023 2023-11-30	FY 2022 2022-11-30	FY 2021 2021-11-30
Total revenue	84	55	77	39	—
Research and development	317	222	189	184	116
General and administrative	53	46	43	38	31
Total operating expenses	370	268	232	222	148
Loss from operations	−286	−213	−155	−184	−118
Interest and other income, net	22	20	11	4	823,000
Loss before income taxes	−264	−193	−144	−180	−117
Provision for income taxes	760,000	270,000	0	0	131,000
Net loss	−264	−194	−144	−180	−117
Net loss per share, basic (in USD per share)	−3.05	−2.88	−2.65	−3.71	−2.73
Net loss per share, diluted (in USD per share)	−3.05	−2.88	−2.65	−3.71	−2.73
Weighted-average number of shares outstanding, basic (in shares)	87	67	54	49	43
Weighted-average number of shares outstanding, diluted (in shares)	87	67	54	49	43

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-11-30	FY 2024 2024-11-30	FY 2023 2023-11-30	FY 2022 2022-11-30	FY 2021 2021-11-30
Cash and cash equivalents	247	110	55	64	81
Marketable securities	346	500	233	—	—
Prepaid expenses and other current assets	14	10	8	9	9
Total current assets	607	619	296	318	311
Operating lease right-of-use assets	51	28	31	12	14
Property and equipment, net	22	18	17	17	11
Restricted cash	1	900,000	901,000	901,000	300,000
Other assets	7	3	4	4	3
Total assets	688	669	356	417	477
Accounts payable	11	11	6	5	7
Accrued expenses and other current liabilities	55	38	25	22	15
Operating lease liabilities, current	3	8	7	6	4
Deferred revenue, current	18	38	48	38	41
Total current liabilities	86	96	87	71	66
Operating lease liabilities, net of current portion	53	20	23	6	9
Deferred revenue, net of current portion	10	26	45	36	59
Total liabilities	149	142	155	113	134
Commitments and contingencies (Note 6)	—	—	—	—	—
Preferred stock, $0.001 par value 10,000,000 shares authorized as of November 30, 2025 and 2024; no shares issued and outstanding as of November 30, 2025 and 2024	0	0	0	0	0
Common stock, $0.001 par value 500,000,000 shares authorized as of November 30, 2025 and 2024; 101,807,484 and 75,870,718 shares issued and outstanding as of November 30, 2025 and 2024, respectively	102,000	76,000	49,000	47,000	45,000
Additional paid-in capital	1,542	1,266	746	709	564
Accumulated other comprehensive income	105,000	150,000	−655,000	−4	−608,000
Accumulated deficit	−1,000	−739	−545	−401	−221
Total stockholders equity	539	527	200	304	342
Total liabilities and stockholders equity	688	669	356	417	477

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-11-30	FY 2024 2024-11-30	FY 2023 2023-11-30	FY 2022 2022-11-30	FY 2021 2021-11-30
Depreciation and amortization	9	9	8	5	3
Stock-based compensation	38	34	34	28	16
Net accretion of discount on marketable securities	−10	−11	−5	426,000	2
Loss on disposal of property and equipment	89,000	31,000	556,000	9,000	128,000
Amortization of operating lease right-of-use assets	10	7	6	5	3
Other	0	286,000	0	201,000	0
Prepaid expenses and other assets	−6	−459,000	2	−1	−5
Accounts payable	−630,000	5	2	85,000	2
Deferred revenue	−37	−29	20	−27	14
Operating lease liabilities	−5	−6	−6	−5	−5
Accrued expenses and other current liabilities	17	12	3	7	6
Net cash used in operating activities	−249	−173	−81	−160	−84
Purchases of marketable securities	−456	−708	−246	−239	—
Maturities of marketable securities	618	460	323	279	239
Purchases of property and equipment	−14	−9	−8	−12	−6
Net cash provided by (used in) investing activities	148	−258	68	27	−108
Proceeds from issuances of common stock and pre-funded warrants, net of issuance costs	235	189	0	95	—
Proceeds from exercise of stock options and pre-funded warrants	2	5	988,000	1	—
Proceeds from issuance of common stock under employee stock purchase plan	2	2	2	2	2
Proceeds from issuances of common stock in "at the market" financing, net of issuance costs	0	290	0	19	150
Repurchase of unvested early exercised stock options	0	−15,000	0	0	—
Net cash provided by financing activities	239	486	3	117	154
Net increase (decrease) in cash, cash equivalents and restricted cash	137	55	−10	−15	−39
Additions to property and equipment included in accounts payable and accrued expenses and other current liabilities	1	2	632,000	1	3
Right-of-use assets recognized in exchange for lease obligations	32	4	24	5	2
Capitalized stock-based compensation related to internal-use software development	20,000	14,000	74,000	69,000	0
Issuance costs related to equity financing included in accrued expenses and other current liabilities	371,000	0	0	—	—
Deferred issuance costs included in accounts payable and accrued expenses and other current liabilities	0	117,000	0	0	—
Deferred issuance costs recognized related to the "at the market" financing	0	394,000	0	72,000	0
Vesting of early exercised stock options	0	33,000	117,000	145,000	239,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Nurix Therapeutics, Inc.'s CIK number?

Nurix Therapeutics, Inc.'s SEC CIK number is 0001549595 (1549595). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Nurix Therapeutics, Inc.'s SEC filings?

All of Nurix Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Nurix Therapeutics, Inc. last report earnings?

Nurix Therapeutics, Inc. (NRIX) most recently filed an earnings 8-K with the SEC on Jul 9, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001549595-26-000038). This is Nurix Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Nurix Therapeutics, Inc.'s most recent earnings 8-K?

Nurix Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed Jul 9, 2026 under accession 0001549595-26-000038. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Nurix Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →